Liberty’s Expeditionary Science and Special Programs Laboratory (X-Lab) develops bioengineering and clinical solutions to challenging medical, commercial and industrial unmet needs. These solutions are derived from novel organisms obtained from government and Liberty's own proprietary collection of extremophile biologics. The X-Lab's multidisciplinary team of microbiologists and bioinformaticians are supported by physicians and experts drawn from military and intelligence communities.
Bioengineering lead candidate (LJ-321) One novel species, designated as LJ-321, is capable of surviving sustained exposure to high-doses of UV radiation that otherwise destroy the DNA of species on Earth. X-Lab scientists have forced directed evolution of LJ-321 to produce UV-resistant compounds. These compounds are being characterized for UV-blocking biological capabilities for use in hydrogels, paints, plastics, and other industrial and commercial materials.
Clinical lead candidate (L-211)
The Expeditionary Science and Special Programs Laboratory is developing another novel organism, designated as LP-888, that secretes a compound that inhibits bacterial efflux pumps. Efflux pumps serve as the principal pathway used by bacteria to develop resistance to antibiotics. The compound produced by L-211 has been shown to reverse antibiotic resistance in a range of human pathogens, to include Methicillin-resistant Staphylococcus aureus (MRSA). L-211 is under investigation by the X-Lab as a co- therapeutic to antibiotics to enhance their effectiveness in defeating antibiotic resistant strains of bacteria.